文献速递糖尿病肥胖与代谢综合征

HMGCR与瑞舒伐他汀调控GLP-1分泌及表达:一项转化研究

HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression-A Translational Study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该转化研究结合MDCS-CC再检查队列(n=3734)、GLUTag细胞实验及小鼠急慢性研究,探讨瑞舒伐他汀对GLP-1分泌的影响。发现无T2D者他汀使用与较高空腹GIP、胰岛素、血糖、胰高血糖素及HOMA-IR相关,而T2D患者他汀使用与较高空腹GLP-1相关。瑞舒伐他汀或Hmgcr敲低减少GLUTag细胞GLP-1分泌并增加Gcg mRNA;小鼠急性瑞舒伐他汀降低餐后GLP-1分泌,慢性给药导致高血糖并升高餐后GLP-1。结论:HMGCR是GLP-1分泌调节因子,可解释他汀相关轻度高血糖,建议处方瑞舒伐他汀后监测血糖。

要点

  • 瑞舒伐他汀或Hmgcr敲低在体外减少GLP-1分泌并增加Gcg mRNA。
  • 小鼠急性瑞舒伐他汀降低餐后GLP-1分泌,慢性给药致高血糖。
  • 处方瑞舒伐他汀后建议监测血糖水平。

核心结论

  • HMGCR被确立为GLP-1分泌的调节因子,为临床观察到的他汀相关轻度高血糖提供了合理解释。
  • 鉴于瑞舒伐他汀对GLP-1分泌的急性负效应,建议处方后监测血糖。

研究设计与样本

  • 在MDCS-CC再检查队列(n=3734)中进行关联研究。
  • 使用GLUTag细胞进行体外研究,并在雌性正常血糖C57Bl/6j小鼠中进行急性和慢性研究。

主要发现

  • 在无T2D个体中,他汀使用与较高空腹GIP、胰岛素、血糖、胰高血糖素及HOMA-IR相关,但与GLP-1无关。
  • 在T2D患者中,他汀使用与较高空腹GLP-1水平相关。
  • 瑞舒伐他汀处理或Hmgcr敲低减少GLUTag细胞GLP-1分泌并增加Gcg mRNA。
  • 瑞舒伐他汀急性减少小鼠餐后GLP-1分泌,而慢性治疗导致高血糖并增加餐后GLP-1水平。
  • Hmgcr敲低对GLP-1分泌的急性效应可通过PCSK9抑制剂靶向细胞内胆固醇来模拟。

临床怎么用

  • 处方瑞舒伐他汀后应监测血糖水平,尤其关注GLP-1分泌的急性抑制效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Statin use is associated with increased risk of type 2 diabetes (T2D) and mild hyperglycemia. The underlying mechanisms are not well studied, and the effect of statin treatment on glucagon-like peptide 1 (GLP-1) secretion or production is unknown. OBJECTIVE: This work aimed to assess the effects of rosuvastatin on GLP-1 secretion and production. METHODS: We performed association studies in the Malmö Diet and Cancer study cardiovascular cohort (MDCS-CC) reexamination cohort, in vitro investigations using GLUTag cells and acute and chronic studies in female, normoglycemic C57Bl/6j mice. RESULTS: Studies in the MDCS-CC reexamination cohort (n = 3734) revealed that in individuals without T2D, statin usage was associated with higher fasting glucose-dependent insulinotropic peptide (GIP), insulin, glucose, glucagon, and homeostatic model assessment of insulin resistance, but not GLP-1. However, in patients with T2D, statin usage was associated with higher fasting GLP-1 levels. Rosuvastatin treatment or 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (Hmgcr) knockdown (KD) reduced GLP-1 secretion and increased Gcg messenger RNA in GLUTag cells. Rosuvastatin acutely reduced postprandial GLP-1 secretion, whereas chronic rosuvastatin treatment in mice caused hyperglycemia and increased postprandial GLP-1 levels. The acute effect of Hmgcr KD on GLP-1 secretion could be mimicked by targeting intracellular cholesterol using a PCSK9 inhibitor. Finally, transcriptomic alterations induced by rosuvastatin were limited to genes involved in cholesterol biosynthesis. CONCLUSION: We have established HMGCR as a regulator of GLP-1 secretion and provide a plausible explanation for the clinically observed mild hyperglycemia associated with statin use. Given the negative acute effect on GLP-1 secretion, monitoring of blood glucose levels is recommended after prescribing rosuvastatin.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Miskelly MG, Lindqvist A, Jujić A, et al. HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression-A Translational Study. J Clin Endocrinol Metab. 2026. PMID: 41206007. doi:10.1210/clinem/dgaf608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。